Selecting Optimal 3L Colorectal Cancer Treatment
Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.
Source: onclive.com
Arvind Dasari News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Arvind Dasari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Arvind Dasari Today - Breaking & Trending Today
FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer
Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Source: onclive.com
Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
For patients with refractory metastatic colorectal cancer, fruquintinib treatment yields a significant and clinically meaningful benefit in terms of overall survival.
Source: oncologynurseadvisor.com
Was the Fruquintinib Trial for Metastatic CRC a Win?
Despite the overall survival benefit associated with fruquintinib, weighing the risks and benefits of the drug remains important; and one oncologist questioned the trial's placebo arm.
Source: medscape.com
Fruquintinib improved survival in patients with refractory metastatic colorectal cancer
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.
Source: news-medical.net